Abstract
Studies have found naltrexone useful in the treatment of diseases other than opiate addiction in which endogenous opioids presumably play a role, such as alcoholism and eating disorders. Some of these studies involve high doses (100-200 mg bid). Because investigational studies with high doses (300 mg/day) reported clinically significant increases in liver enzyme levels, the authors measured a spectrum of liver function parameters in response to high doses of naltrexone in a double-blind, crossover trial (100 mg bid) followed by an open-label period (200 mg bid). They observed no adverse clinical or laboratory changes in liver function in association with high-dose naltrexone therapy in eating disorders.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alanine Transaminase / drug effects
-
Anorexia Nervosa / drug therapy*
-
Aspartate Aminotransferases / drug effects
-
Bulimia / drug therapy*
-
Cross-Over Studies
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Female
-
Humans
-
L-Lactate Dehydrogenase / drug effects
-
Liver / drug effects*
-
Liver Function Tests*
-
Middle Aged
-
Naltrexone / administration & dosage
-
Naltrexone / pharmacology*
-
Naltrexone / therapeutic use*
-
Narcotic Antagonists / administration & dosage
-
Narcotic Antagonists / pharmacology*
-
Narcotic Antagonists / therapeutic use*
Substances
-
Narcotic Antagonists
-
Naltrexone
-
L-Lactate Dehydrogenase
-
Aspartate Aminotransferases
-
Alanine Transaminase